Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Inflammatory Bowel Disease: Supporting Calmer Flares and Gut Healing
Transcript
- 0:00SPEAKER_00: Welcome to the CyberNocel Podcast.
- 0:01SPEAKER_01: Aaron Powell Thanks for having me back.
- 0:03SPEAKER_00: Yeah.
- 0:03SPEAKER_00: So today, I mean, imagine your body's defense system, the very thing that's, you know, designed to protect you from harm, suddenly just forgets how to turn off.
- 0:12SPEAKER_01: Aaron Powell Right.
- 0:13SPEAKER_01: It just misfires completely.
- 0:15SPEAKER_00: Aaron Powell Exactly.
- 0:16SPEAKER_00: Instead of attacking a passing virus, it wages this relentless decades-long war on your own digestive tract.
- 0:23SPEAKER_00: If you've ever had a severe bout of food poisoning, you know that absolute misery of gut inflammation.
- 0:29SPEAKER_01: Oh, absolutely.
- 0:30SPEAKER_01: It's awful.
- 0:31SPEAKER_00: Right.
- 0:31SPEAKER_00: Now imagine waking up with that feeling every single day with literally no end in sight.
- 0:36SPEAKER_00: That is the grueling baseline for someone living with inflammatory bowel disease or IBD.
- 0:41SPEAKER_01: Aaron Powell It is an incredibly heavy burden.
- 0:43SPEAKER_01: Yeah.
- 0:44SPEAKER_01: And it's why our mission for this deep dive is just so vital.
- 0:47SPEAKER_01: We're exploring the absolute frontier of regenerative medicine today.
- 0:50SPEAKER_01: Yeah.
- 0:50SPEAKER_01: Specifically as an adjunct therapy for this notoriously difficult condition.
- 0:55SPEAKER_01: We are looking at the clinical materials and medical protocols from Cyronicell.
- 0:58SPEAKER_00: Aaron Powell Right.
- 0:59SPEAKER_00: And just to give some context here, Cyrona Cell is a doctor-led stem cell therapy and regenerative medicine center.
- 1:06SPEAKER_00: And they're based in Kuala Lumpur, Malaysia.
- 1:09SPEAKER_00: Trevor Burrus, Jr.
- 1:09SPEAKER_00: Right.
- 1:10SPEAKER_00: And what really stands out in their source documents is their service area.
- 1:13SPEAKER_00: I mean, they're treating local patients in Southeast Asia, obviously.
- 1:17SPEAKER_00: But they also have this massive influx of international patients flying in from places like Australia, the Middle East, specifically just to access this structured care.
- 1:27SPEAKER_01: Aaron Ross Powell, which really tells you something about the demand.
- 1:30SPEAKER_01: But when analyzing a clinic operating on a global scale like that, we have to maintain a very specific dual focus.
- 1:37SPEAKER_00: Aaron Ross Powell Make sure it's legit, baby.
- 1:39SPEAKER_01: Trevor Burrus Exactly.
- 1:40SPEAKER_01: We approach this with a curious and hopeful lens, absolutely, because the underlying biology here is revolutionary.
- 1:46SPEAKER_01: But we also have to apply a really critically grounded lens.
- 1:49SPEAKER_01: Right.
- 1:50SPEAKER_01: Our goal today is to separate the actual peer-reviewed science from the internet hype.
- 1:55SPEAKER_01: We're going to look strictly at how medically supervised cell therapy actually works inside the human body.
- 1:59SPEAKER_00: Aaron Powell Okay.
- 2:00SPEAKER_00: Let's unpack this.
- 2:01SPEAKER_00: Because before we can really understand the solution, I feel like we have to deeply understand the specific biological problem we're trying to solve.
- 2:09SPEAKER_01: That's a great place to start.
- 2:11SPEAKER_00: Let's start at the battlefield itself.
- 2:13SPEAKER_00: What is actually happening at a microscopic level in the gut of an IBD patient?
- 2:17SPEAKER_01: Aaron Powell Well, if we connect this to the bigger picture of the human immune system, inflammatory bowel disease is essentially a chronic condition of inappropriate defense.
- 2:29SPEAKER_01: Yeah.
- 2:30SPEAKER_01: When you get a cut on your arm, your immune system rushes white blood cells to the area, causing it to get red, swollen, hot.
- 2:36SPEAKER_00: Aaron Powell Right, the normal stuff.
- 2:38SPEAKER_01: Exactly.
- 2:38SPEAKER_01: That's acute inflammation, and it's a good thing.
- 2:40SPEAKER_01: It heals you.
- 2:41SPEAKER_01: But in IBD, that inflammatory cascade is triggered in the gut and the off switch just gets broken.
- 2:47SPEAKER_00: Oh wow.
- 2:47SPEAKER_00: So it just stays on.
- 2:48SPEAKER_01: It stays on for way too long.
- 2:50SPEAKER_01: It's constantly attacking harmless bacteria, food, and literally the gut lining itself.
- 2:55SPEAKER_01: Within IBD, the sources focus on two main conditions which behave a bit differently.
- 2:59SPEAKER_01: Uh Crohn's disease and ulcerative colitis.
- 3:02SPEAKER_00: How do those two differ actually, like in terms of the physical damage?
- 3:06SPEAKER_01: Aaron Powell Well, with Crohn's disease, the inflammation often appears in patches anywhere along the digestive tract.
- 3:12SPEAKER_01: So from the mouth all the way to the end of the bowel.
- 3:14SPEAKER_00: Okay.
- 3:15SPEAKER_01: And critically it is transmural, meaning the inflammation can reach incredibly deep, actually burning through all the tissue layers of the digestive tract.
- 3:23SPEAKER_00: Aaron Powell That sounds incredibly painful.
- 3:25SPEAKER_00: And what about ulcerative colitis?
- 3:27SPEAKER_01: Ucerative colitis, on the other hand, usually features continuous inflammation.
- 3:32SPEAKER_01: And it primarily affects just the innermost lining of the colon in one uninterrupted area.
- 3:38SPEAKER_00: Aaron Powell The source materials, I mean, they paint a really stark picture of the daily reality for these patients.
- 3:43SPEAKER_00: It's not just a stomachache.
- 3:44SPEAKER_01: Not at all.
- 3:45SPEAKER_00: We are talking about severe, like doubling over cramps, constant diarrhea, and this deep cellular level fatigue.
- 3:52SPEAKER_01: Aaron Powell Right, because the damaged gut simply cannot absorb nutrients properly anymore.
- 3:57SPEAKER_00: Exactly.
- 3:57SPEAKER_00: And over time, that chronic inflammation quietly destroys the bowel architecture between these major flares.
- 4:04SPEAKER_00: It leads to open ulcers, narrowing of the digestive tract, which they call striptures, severe bleeding, and you know, the development of fistulas.
- 4:12SPEAKER_01: And we really can't ignore the immense psychological weight of this condition either.
- 4:16SPEAKER_01: There is this constant, ambient anxiety for the patient.
- 4:20SPEAKER_00: Oh, I can imagine.
- 4:21SPEAKER_01: The fear of a sudden flare-up just completely dictates a person's life.
- 4:26SPEAKER_00: It disrupts careers, strains family dynamics, forces you to map out every public restroom before you even leave the house?
- 4:32SPEAKER_01: Precisely.
- 4:33SPEAKER_01: And while genetics certainly play a foundational role, environmental factors like lingering infections, smoking, diet, and severe stress can shape that immune response and trigger these devastating flares.
- 4:44SPEAKER_00: Aaron Powell So how does standard medicine handle a fire that just refuses to go out?
- 4:49SPEAKER_01: Well, the standard medical playbook relies heavily on immunosuppression.
- 4:53SPEAKER_01: Medicines like corticosteroids or targeted biologics.
- 4:56SPEAKER_01: They're generally designed to block key inflammatory signals in the body.
- 5:00SPEAKER_01: They try to chemically interrupt the immune response to just force the inflammation down.
- 5:05SPEAKER_00: Aaron Powell It makes me think of an analogy.
- 5:07SPEAKER_00: Relying entirely on those standard drugs to heal the gut is, well, it's like simply muting a fire alarm while the house is still smoldering.
- 5:15SPEAKER_01: Aaron Powell That's yeah, that's a very accurate way to look at it.
- 5:18SPEAKER_00: You don't hear the blaring noise of the symptoms anymore, but the structural damage to the walls is still happening in the background.
- 5:24SPEAKER_01: Exactly.
- 5:25SPEAKER_01: Blocking the signal is often totally necessary for immediate symptom control.
- 5:29SPEAKER_01: But there's a significant catch.
- 5:32SPEAKER_01: Because the drugs suppress the immune system, they leave the patient vulnerable to other infections.
- 5:37SPEAKER_00: Right, because you turned off the defense system entirely.
- 5:40SPEAKER_01: Exactly.
- 5:40SPEAKER_01: And over time, many patients actually develop antibodies against the drugs themselves.
- 5:46SPEAKER_00: Oh, wow.
- 5:46SPEAKER_00: So the drugs just stop working.
- 5:48SPEAKER_01: Yeah, they eventually stop responding or they struggle with really heavy systemic side effects.
- 5:53SPEAKER_00: Which brings us to a really critical point in this deep dive.
- 5:56SPEAKER_00: If the drugs just block signals, how does the body actually repair the deep tissue damage that's already been done?
- 6:04SPEAKER_00: Right.
- 6:04SPEAKER_00: How do you fix the smoldering house without adding more toxic burden to the patient?
- 6:08SPEAKER_01: Aaron Powell This raises an important question.
- 6:11SPEAKER_01: And it's exactly the question that drives the shift toward regenerative medicine.
- 6:15SPEAKER_01: When standard symptom control reaches its limit, we have to look at biological solutions.
- 6:21SPEAKER_00: Solutions that actively support tissue regeneration.
- 6:24SPEAKER_01: Exactly.
- 6:25SPEAKER_01: This is where the concept of introducing biological support units comes into play.
- 6:29SPEAKER_00: Okay, so enter stem cell therapy.
- 6:30SPEAKER_00: But wait, let me stop you right there.
- 6:32SPEAKER_00: Because the phrase stem cells, it carries a lot of baggage for the general public.
- 6:37SPEAKER_01: It does.
- 6:37SPEAKER_01: It really does.
- 6:38SPEAKER_00: Are we talking about embryonic stem cells here?
- 6:40SPEAKER_00: Because I know that's a major ethical red flag and a massive safety concern for a lot of people.
- 6:45SPEAKER_01: Aaron Ross Powell A very necessary distinction to make.
- 6:47SPEAKER_01: The Cirona cell protocols are explicitly clear on this.
- 6:50SPEAKER_01: They do not use embryonic stem cells.
- 6:52SPEAKER_00: Okay, that's good to know.
- 6:54SPEAKER_01: Yeah.
- 6:54SPEAKER_01: The treatments utilize human Wharton's jelly misenchymal stem cells, which is commonly abbreviated as WJMSECs.
- 7:02SPEAKER_00: Wharton's jelly, what exactly is that?
- 7:04SPEAKER_01: So Wharton's jelly is a gelatinous substance found inside the human umbilical cord.
- 7:09SPEAKER_00: Oh, the umbilical cord.
- 7:10SPEAKER_01: Okay, right.
- 7:11SPEAKER_01: These specific stem cells are derived from healthy, full-term umbilical cords.
- 7:16SPEAKER_01: They are ethically sourced, obtained only after a healthy birth.
- 7:19SPEAKER_00: With the mother's consent, obviously.
- 7:21SPEAKER_01: With the explicit informed consent of the donor mother, yes.
- 7:25SPEAKER_01: It's a tissue that is usually just discarded as medical waste.
- 7:28SPEAKER_00: Right.
- 7:29SPEAKER_01: But it happens to be rich in incredibly potent young mesenchymal stem cells.
- 7:35SPEAKER_00: Aaron Powell So to answer the question about how they repair tissue damage, we really have to rethink how we view a medical treatment.
- 7:42SPEAKER_01: Absolutely.
- 7:42SPEAKER_00: Because these cells they don't act like a traditional targeted pharmaceutical drug, right?
- 7:46SPEAKER_00: They aren't just chemical compounds blocking a single receptor.
- 7:49SPEAKER_01: Aaron Powell Far from it.
- 7:50SPEAKER_01: They are dynamic living cells.
- 7:52SPEAKER_01: When these mesenchymal stem cells are introduced into a patient's body, they behave more like intelligent support units.
- 7:59SPEAKER_00: What do you mean by intelligent?
- 8:00SPEAKER_01: Well, they have this unique ability called homing, meaning they can actually sense chemical distress signals in the body and migrate toward areas of high inflammation.
- 8:09SPEAKER_00: Like the damaged gut.
- 8:10SPEAKER_01: Exactly, like the gut.
- 8:11SPEAKER_01: But once they arrive, they don't necessarily turn into new gut tissue themselves.
- 8:16SPEAKER_01: Instead, they release a complex cocktail of anti-inflammatory messengers and growth factors.
- 8:21SPEAKER_00: Here's where it gets really interesting for me.
- 8:23SPEAKER_00: It's a shift in the entire biological environment.
- 8:27SPEAKER_00: So these cells aren't like assassins hunting down a single trigger.
- 8:31SPEAKER_00: Right.
- 8:32SPEAKER_00: They're more like a general contractor stepping onto a chaotic construction site.
- 8:36SPEAKER_00: They survey the damage, hand out blueprints, and start telling the immune system's demolition crew to calm down so the rebuilding can actually start.
- 8:44SPEAKER_01: I love that visualization.
- 8:46SPEAKER_01: And to take that analogy further, the general contractor actually changes the behavior of the workers on site.
- 8:52SPEAKER_01: Ah, so.
- 8:52SPEAKER_01: In the gut, you have these immune cells called macrophages.
- 8:56SPEAKER_01: During an IBD flare, these macrophages are stuck in aggressive pro-inflammatory attack mode, what scientists call an M1 state.
- 9:04SPEAKER_00: Okay, the demolition crew.
- 9:06SPEAKER_01: Exactly.
- 9:07SPEAKER_01: The signals released by the stem cells actually coax those macrophages to flip into an M2 state.
- 9:14SPEAKER_00: And what's the M2 state?
- 9:15SPEAKER_01: That's the anti-inflammatory tissue repair mode.
- 9:18SPEAKER_01: The stem cells are organizing the repair and guiding the existing immune system toward a much calmer pattern.
- 9:24SPEAKER_00: And because several biological pathways are shifting all at once, this approach helps reduce inflammation across the entire bowel rather than just chasing one single inflammatory protein like a standard biologic drug does.
- 9:36SPEAKER_01: Exactly the point.
- 9:38SPEAKER_01: The ultimate goal of all this cellular coordination is to achieve what gastroenterologists call mucosal healing.
- 9:44SPEAKER_00: Mucosal healing.
- 9:45SPEAKER_00: So what does that actually look like for the patient?
- 9:47SPEAKER_00: How does it change their day-to-day life?
- 9:49SPEAKER_01: Aaron Powell Well, the mucosa is the innermost lining of the gastrointestinal tract.
- 9:53SPEAKER_01: In a healthy person, it's a tight, robust barrier.
- 9:57SPEAKER_01: Right.
- 9:57SPEAKER_01: But in an IBD patient, it looks like a torn-up battlefield full of bleeding ulcers and friable fragile tissue.
- 10:03SPEAKER_01: Mucosal healing means that physical barriers being structurally repaired.
- 10:07SPEAKER_00: So the ulcers actually close up.
- 10:08SPEAKER_01: Yes.
- 10:09SPEAKER_01: The ulcers in the digestive tract start to close over.
- 10:12SPEAKER_01: The lining becomes significantly less fragile.
- 10:15SPEAKER_00: And as that lining strengthens, the bleeding drops, the pain drops.
- 10:20SPEAKER_01: And crucially, because the tissue is healthier and the barrier is restored, the patient's gut can finally start absorbing nutrients from food again.
- 10:28SPEAKER_00: Oh, which combats the fatigue?
- 10:30SPEAKER_01: Yes, it directly combats that severe draining fatigue that comes with IBD.
- 10:35SPEAKER_01: It's moving beyond just muting the fire alarm, you know?
- 10:38SPEAKER_01: It is putting out the embers and rebuilding the walls.
- 10:41SPEAKER_00: Knowing how these cells work in theory is absolutely fascinating, but putting living cells into a human body requires immense safety, immense structure, and just a lot of quality control.
- 10:52SPEAKER_01: Oh, absolutely.
- 10:52SPEAKER_00: How does a clinic actually do this responsibly?
- 10:55SPEAKER_00: Because the leap from a laboratory theory to an actual human being sitting in a treatment chair is huge.
- 11:00SPEAKER_01: It is a massive leap, and that is exactly why the source material spends so much time detailing the rigorous, science-first approach at Cyrona Cell.
- 11:09SPEAKER_00: Even their name speaks to this philosophy, right?
- 11:11SPEAKER_01: Yeah.
- 11:12SPEAKER_01: Cyrona is named after an ancient Celtic goddess of health, healing, and protection.
- 11:17SPEAKER_01: It reflects their core focus on safe, heavily scrutinized, science-led care.
- 11:22unknown: Trevor Burrus, Jr.
- 11:23SPEAKER_00: Explicitly rejecting the overnight quick fix promises.
- 11:26SPEAKER_00: Trevor Burrus, Jr.
- 11:26SPEAKER_01: Exactly.
- 11:27SPEAKER_01: The stuff you unfortunately see sometimes in the unregulated corners of this industry.
- 11:31SPEAKER_00: Yeah, let's walk through those safety protocols because if you are evaluating any kind of advanced therapy, these are the benchmarks you absolutely want to look for.
- 11:38SPEAKER_01: For sure.
- 11:39SPEAKER_00: The first thing that stood out in the materials is the quality control of the cells themselves.
- 11:43SPEAKER_01: Aaron Powell The production standards are exceptionally strict.
- 11:46SPEAKER_01: Cyrona cell uses what are called early passage cells.
- 11:49SPEAKER_00: Early passage.
- 11:50SPEAKER_00: What does that mean?
- 11:51SPEAKER_01: Aaron Ross Powell When stem cells are grown in a lab, each time they multiply and are moved to a new flask, it's called a passage.
- 11:57SPEAKER_01: If you culture them too many times, they age, lose their potency, and become unstable.
- 12:02SPEAKER_00: Oh, I see.
- 12:03SPEAKER_00: So you want the fresh ones.
- 12:04SPEAKER_01: Using early passage cells ensures the treatment is as robust and effective as possible.
- 12:09SPEAKER_01: Furthermore, these cells are produced under CGMP and ISO 9001 certified quality systems.
- 12:15SPEAKER_00: Let's decode that for a second.
- 12:17SPEAKER_00: CGMP stands for current good manufacturing practices.
- 12:20SPEAKER_00: It's essentially the global gold standard for making sure biological products are consistently produced, pure, and safe.
- 12:27SPEAKER_01: Aaron Powell Right.
- 12:28SPEAKER_01: And the laboratory itself operates under BSL2 standards, which means biosafety level two.
- 12:33SPEAKER_00: So very secure.
- 12:34SPEAKER_01: It's a highly controlled clinical environment designed specifically to handle human cells safely, using specialized airflow and sterile hoods to ensure zero contamination.
- 12:44SPEAKER_00: That's reassuring.
- 12:45SPEAKER_01: They conduct incredibly strict checks for cellular identity, sterility, and viability on every single batch of cells before a doctor is ever allowed to administer it.
- 12:54SPEAKER_00: And equally important is what they do not use.
- 12:56SPEAKER_00: The materials are very clear on this.
- 12:58SPEAKER_00: We already covered that there are no embryonic stem cells used.
- 13:00SPEAKER_00: Correct.
- 13:01SPEAKER_00: There are also no experimental induced pluripotent stem cells used in their clinical services.
- 13:06SPEAKER_00: And for their standard protocols, there is no open surgery involved.
- 13:10SPEAKER_01: The delivery is designed to be minimally invasive.
- 13:12SPEAKER_01: For systemic issues like IBD, the cells are typically delivered via an intravenous infusion, so an IV drip.
- 13:19SPEAKER_00: Okay.
- 13:19SPEAKER_00: Fairly straightforward.
- 13:20SPEAKER_01: In some specific cases, a doctor might use targeted local injections.
- 13:25SPEAKER_01: But let's look at the actual patient journey because it's a very structured medical pathway.
- 13:30SPEAKER_01: It starts with a comprehensive medical evaluation.
- 13:34SPEAKER_00: Patients aren't just walking into a clinic and getting an IV on demand, right?
- 13:37SPEAKER_01: No, not at all.
- 13:38SPEAKER_01: There is a heavy vetting process.
- 13:40SPEAKER_01: The patient shares their recent colonoscopy reports, comprehensive blood and stool tests, imaging, and their full medication list.
- 13:48SPEAKER_00: And the medical team reviews all of this.
- 13:50SPEAKER_01: The medical team reviews all of this data to check for active infections that might interfere with the therapy.
- 13:56SPEAKER_01: They spend time explaining the actual limitations of regenerative medicine, and they set practical, realistic goals.
- 14:03SPEAKER_00: So they aren't promising a magical overnight cure.
- 14:06SPEAKER_01: Never.
- 14:06SPEAKER_01: They're aiming for tangible improvements, like reducing the number of urgent bathroom trips a day or lessening the severity of the daily cramping.
- 14:15SPEAKER_00: Then comes the lab preparation phase, where those strict identity and sterility checks happen.
- 14:20SPEAKER_00: Then the administration itself, which as we mentioned, is usually a simple IV drip, while the patient rests comfortably in a treatment chair.
- 14:26SPEAKER_00: And finally, the monitoring and follow-up phase.
- 14:30SPEAKER_00: This isn't a fire and forget treatment.
- 14:32SPEAKER_00: They track clinical symptoms and key biological markers over time.
- 14:37SPEAKER_01: Specifically, they track markers like CRP and calprotectin.
- 14:40SPEAKER_00: What are those?
- 14:41SPEAKER_01: CRP, or C reactive protein, is a protein made by your liver that acts like a loud fire alarm in your blood whenever there is systemic inflammation.
- 14:50SPEAKER_00: Okay, got it.
- 14:51SPEAKER_00: And calprotectin.
- 14:53SPEAKER_01: Calprotectin is a protein found specifically in white blood cells in your gut.
- 14:58SPEAKER_01: It serves as a direct physical measure of active intestinal inflammation.
- 15:02SPEAKER_00: Oh, so doctors can actually see the numbers go down.
- 15:04SPEAKER_01: Gastroenterologists rely heavily on both to see if a treatment is actually working.
- 15:08SPEAKER_01: The Sirona medical team also adjusts personalized nutrition advice and stress management tools so the patient's entire lifestyle stays aligned with the healing process.
- 15:17SPEAKER_00: Okay, I have to play the skeptic here for a second.
- 15:20SPEAKER_00: Because there are a lot of clinics out there promising absolute miracles, especially to international patients flying in from places like Australia or the Middle East who are just desperate for relief.
- 15:30SPEAKER_01: Yeah, the desperation is real.
- 15:32SPEAKER_00: How does a patient know this isn't just exaggerated marketing?
- 15:35SPEAKER_01: What's fascinating here is how the materials directly address that exact skepticism.
- 15:41SPEAKER_01: Cyronacel's medical team operates on a strict principle of transparent advice.
- 15:46SPEAKER_00: Meaning what exactly?
- 15:47SPEAKER_01: They explicitly state that if their doctors review your colonoscopies and blood work and believe you are unlikely to benefit from their program, they will simply say no.
- 15:56SPEAKER_00: Wait, really?
- 15:58SPEAKER_00: They turn people away?
- 16:00SPEAKER_01: Yes.
- 16:00SPEAKER_01: They will tell the patient that cell therapy isn't appropriate for their specific disease state.
- 16:05SPEAKER_00: That is a massive distinction.
- 16:06SPEAKER_00: I mean, a clinic willing to turn away a paying international patient because the science doesn't support the treatment that builds an enormous amount of credibility.
- 16:15SPEAKER_00: Trevor Burrus, Jr.
- 16:15SPEAKER_01: Their priority is clearly long-term trust and medical integrity, not one-time procedures.
- 16:20SPEAKER_01: Furthermore, they constantly reinforce every patient that this regenerative medicine is positioned strictly as an adjunct therapy.
- 16:26SPEAKER_00: An adjunct, so a biological support system.
- 16:29SPEAKER_01: It is absolutely not a replacement for your primary gastroeneurologist.
- 16:34SPEAKER_01: And it does not replace emergency treatment or surgery if those extreme interventions are medically necessary.
- 16:40SPEAKER_00: So it's about adding a highly advanced biological tool to the toolkit, not throwing the rest of your medical tools away.
- 16:46SPEAKER_01: Precisely.
- 16:47SPEAKER_00: Since the clinic focuses so heavily on science and facts over hype, let's look at the actual human data.
- 16:53SPEAKER_00: Show me the proof.
- 16:55SPEAKER_00: What does the actual peer-reviewed research show about stem cell therapy for IBD?
- 17:00SPEAKER_01: Well, the clinical evidence is still developing, which is important to note for any advanced therapy.
- 17:04SPEAKER_01: But there are two specific, highly compelling human studies highlighted in the sources that show exactly where this cell care fits into the IBD puzzle.
- 17:12SPEAKER_00: Okay, let's hear them.
- 17:13SPEAKER_01: The first is a pilot study out of Nanjing University in China.
- 17:17SPEAKER_00: Right.
- 17:17SPEAKER_00: This one focused on Crohn's disease, specifically complex pyrianal fistulas.
- 17:22SPEAKER_00: For those who aren't familiar, a fistula is basically an abnormal infected tunnel that forms between the bowel and the skin near the anus.
- 17:29SPEAKER_01: It is an incredibly painful, isolating complication of Crohn's that is notoriously difficult to heal with standard drugs.
- 17:36SPEAKER_00: Yeah, just awful.
- 17:38SPEAKER_00: So what did the study do?
- 17:39SPEAKER_01: In this Nanjing University trial, adults suffering from these complex fistulas received a single local injection of umbilical cord-derived stem cells directly into the tissues surrounding the fistula.
- 17:52SPEAKER_00: And how did they measure success?
- 17:54SPEAKER_01: The researchers didn't just ask patients how they felt.
- 17:57SPEAKER_01: At the 24-week mark, they used objective MRI imaging alongside symptom reviews to check their progress.
- 18:04SPEAKER_00: And what did the MRIs show?
- 18:06SPEAKER_01: They found that a significant portion of the patients showed promising structural healing of the tracts.
- 18:11SPEAKER_01: And crucially, the short-term safety profile look highly acceptable.
- 18:14SPEAKER_01: Wow.
- 18:15SPEAKER_01: Even a partial closure of a complex fistula can massively reduce daily pain, stop chronic drainage, and fundamentally give a patient their quality of life back.
- 18:24SPEAKER_00: That's a huge deal for someone whose Crohn's has just stopped responding to traditional surgery or biologics.
- 18:30SPEAKER_00: What about the second study?
- 18:31SPEAKER_01: The second study is linked to Heening University, also in China.
- 18:34SPEAKER_01: This one focused on ulcerative colitis.
- 18:36SPEAKER_01: Specifically, they looked at a tough, demographic, moderate to severe UC patients who are simply not responding well to standard immunosuppressive drugs.
- 18:47SPEAKER_00: These are the patients whose fire alarms couldn't be muted anymore and the house was burning down.
- 18:52SPEAKER_01: Precisely.
- 18:52SPEAKER_01: In this trial, these non-responding patients were given intravenous infusions of human umbilical cord cells once a month for two consecutive months.
- 19:01SPEAKER_00: Okay, and the results?
- 19:02SPEAKER_01: The results for those who responded to the therapy were highly significant.
- 19:05SPEAKER_01: They saw vastly improved mayo scores.
- 19:08SPEAKER_00: Let's clarify the mayo score for a second.
- 19:10SPEAKER_00: That's a clinical index used by doctors to measure disease severity, right?
- 19:14SPEAKER_01: Yes, exactly.
- 19:15SPEAKER_00: So an improved score basically translates to a patient experiencing significantly less rectal bleeding, far fewer urgent bathroom trips, and a physician physically observing less damage during an exam.
- 19:27SPEAKER_01: Exactly.
- 19:28SPEAKER_01: And speaking of physical observation, they had tangibly better endoscopy results.
- 19:33SPEAKER_01: When doctors put a camera into the colon, instead of seeing a bloody, friable, inflamed mess, they could physically see the improvement in the gut lining.
- 19:41SPEAKER_00: That's incredible.
- 19:42SPEAKER_01: The blood markers of inflammation actually dropped, while their systemic anti-inflammatory balance improved.
- 19:48SPEAKER_01: We are talking about mucosal healing happening in real time.
- 19:52SPEAKER_00: So I noticed the study did include a caveat.
- 19:55SPEAKER_00: It noted that a patient's age may affect their cellular response to the treatment.
- 20:00SPEAKER_01: Yes, it did.
- 20:00SPEAKER_00: Which again highlights why that initial medical evaluation with the Cyreno cell doctors is so critical.
- 20:06SPEAKER_00: You can't just apply a blanket expectation to every age group.
- 20:09SPEAKER_01: It absolutely supports the need for continued larger clinical trials to refine the dosing and timing.
- 20:16SPEAKER_01: But what these studies strongly highlight is the proof-of-concept immune regulation via cellular therapy can fundamentally help the gut heal itself when standard drugs fail.
- 20:26SPEAKER_00: Now, alongside the stem cells, the serono cell materials introduce another fascinating biological component to their protocols, uh exosome therapy.
- 20:34SPEAKER_00: Yes.
- 20:34SPEAKER_00: They offer this as an added value service to amplify the treatment.
- 20:38SPEAKER_00: What exactly is an exosome?
- 20:39SPEAKER_01: To understand exosomes, we have to look closer at how cells communicate.
- 20:43SPEAKER_01: Exosomes are best understood as microscopic, nano-sized messenger packets that are naturally released by stem cells.
- 20:49SPEAKER_00: Okay, messenger packets.
- 20:51SPEAKER_01: Because they are so tiny, they can easily cross biological barriers.
- 20:55SPEAKER_01: Inside these little packets is a dense cargo of the various signals, microRNAs, and growth factors that support tissue repair and calm inflammation.
- 21:05SPEAKER_00: So what happens when you add them to the treatment?
- 21:08SPEAKER_01: By utilizing concentrated exosome therapy alongside the live stem cells, you are essentially amplifying the healing instructions being sent into the body.
- 21:17SPEAKER_00: Wait, so if the stem cells are the general contractors arriving on the construction site, are the exosomes basically the thousands of text messages they're sending out to the immune system and the gut lining to get the repair work done faster?
- 21:30SPEAKER_01: That is exactly what they are.
- 21:31SPEAKER_01: They are the communication packets carrying the explicit instructions for repair from the stem cells directly to the damaged tissues of the gut.
- 21:38SPEAKER_00: That makes perfect sense.
- 21:39SPEAKER_01: Used together, the stem cells provide the sustained cellular presence, and the exosomes flood the zone with repair signals, creating a highly coordinated biological response.
- 21:48SPEAKER_00: So, what does this all mean?
- 21:50SPEAKER_00: Let's synthesize this entire deep dive.
- 21:53SPEAKER_00: For those suffering from the relentless, painful, isolating cycle of inflammatory bowel disease, umbilical cord direction.
- 22:00SPEAKER_00: Stem cell therapy is not a magical cure.
- 22:02SPEAKER_00: Right.
- 22:03SPEAKER_00: We need to be clear.
- 22:04SPEAKER_00: Currently, there is no proven medical cure for IBD.
- 22:08SPEAKER_00: But what we are looking at with Cyrenacells protocols is a highly sophisticated medically supervised support system.
- 22:15SPEAKER_01: It is about changing the underlying environment of the gut.
- 22:18SPEAKER_01: It is a biological tool designed to act as an adjunct to your current gastroenterology care, using advanced cellular communication to coax the immune system back toward peace, repair the physical damage, and achieve real mucosal healing.
- 22:32SPEAKER_01: It's about supporting long-term comfort with honest, realistic expectations.
- 22:36SPEAKER_00: If you are dealing with IBD or you love someone who is, and you want to explore whether a structured, doctor-led regenerative program fits your specific situation, the pathway is remarkably straightforward.
- 22:47SPEAKER_01: It really is.
- 22:47SPEAKER_00: You don't have to guess.
- 22:49SPEAKER_00: You can start with a simple, calm review of your medical reports, your recent colonoscopies, and your current medications with the medical team at Sarona Cell?
- 22:58SPEAKER_00: It's a pragmatic evaluation to see if this advanced therapy safely fits into your wider care plan.
- 23:04SPEAKER_01: And as we wrap up this exploration of the frontier of regenerative medicine, I'm going to leave you with this final thought.
- 23:09SPEAKER_01: If our bodies can be biologically reminded how to heal using the very cellular messengers that help build us in the womb, what other chronic lifelong conditions are simply waiting for us to learn how to speak their cellular language?